Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the company has entered into a settlement agreement with Zydus Pharmaceutical (USA), Inc. and Cadila Healthcare Limited (collectively, "Zydus") involving the ongoing patent litigation regarding Zydus' Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR (extended-release topiramate) capsules. The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR on January 1, 2023, or earlier under certain circumstances. The agreement will be submitted to the applicable governmental agencies.
Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR. Patent protection for Trokendi XR expires no earlier than 2027.
Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases.